Aptevo Therapeutics Inc. (APVO) Ownership
APVO ownership summary
as of October 18, 2026- Institutions
- 2.9% of shares outstanding
- Insiders
- 4.15% of shares outstanding
- Shares outstanding
- 1.8M
- Float
- 1.7M shares available to trade
- Short interest
- 7.69% 119K shares short
- Days to cover
- 0.62 short interest down 36.4% vs prior month
- Institutions 2.88%
- Insiders 4.15%
- Other investors 92.96%
APVO top institutional holders
15 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | GSA Capital Partners LLP | 1.19% | 22K | $34,893 | +1,901 (+9.7%) | June 30, 2026 |
| 2 | Vanguard Capital Management, LLC | 0.70% | 13K | $20,595 | — | June 30, 2026 |
| 3 | Geode Capital Management, LLC | 0.60% | 11K | $17,530 | −2,516 (−18.9%) | June 30, 2026 |
| 4 | Vanguard Fiduciary Trust Co | 0.23% | 4,142 | $6,710 | — | June 30, 2026 |
| 5 | UBS Group AG | 0.04% | 730 | $1,183 | −2,715 (−78.8%) | June 30, 2026 |
| 6 | Advisor Group Holdings, Inc. | 0.02% | 360 | $583 | — | June 30, 2026 |
| 7 | SBI Securities Co Ltd | 0.01% | 109 | $177 | — | June 30, 2026 |
| 8 | Barclays PLC | <0.01% | 31 | $50 | +31 (0.0%) | June 30, 2026 |
| 9 | CWM, LLC duplicate | <0.01% | 5 | $8 | +5 (0.0%) | March 31, 2026 |
| 10 | Danske Bank A/S. | <0.01% | 1 | $2 | — | June 30, 2026 |
| 11 | Tower Research Capital LLC | 0.00% | — | — | −92 (−100.0%) | March 31, 2026 |
| 12 | Tradewinds Capital Management, LLC | 0.00% | — | — | −13 (−100.0%) | March 31, 2026 |
| 13 | FMR Inc | 0.00% | — | — | −7 (−100.0%) | March 31, 2026 |
| 14 | Citigroup Inc | 0.00% | — | — | −2,756 (−100.0%) | March 31, 2026 |
| 15 | Bank of America Corp | 0.00% | — | — | −7 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 15, 3 holders added 1,937 shares and 7 cut 8,106.
APVO top mutual fund and ETF holders
2 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.35% | 6,351 | $10,289 | −34 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.09% | 1,548 | $2,508 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
APVO insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-22 | Kevin C Tang | Sell | $309.32 | 5,802 | $1.8M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
APVO shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns APVO
Institutional investors own 2.9% of Aptevo Therapeutics's shares and insiders 4.15%. The largest holder is GSA Capital Partners LLP with 1.19% of the shares (22K), as of June 30, 2026. Among the top 15 institutions, 3 added shares and 7 reduced their stake in the latest filings. Short interest is 7.69% of the float, or 0.62 days of average trading volume. The share count rose 2,932.8% since 2016.
Related: APVO analyst forecast, APVO key metrics. See the APVO stock overview for the latest quote and news.
APVO ownership FAQ
Who owns the most Aptevo Therapeutics stock?
The largest shareholders of Aptevo Therapeutics are GSA Capital Partners LLP (1.19%), Vanguard Capital Management, LLC (0.70%), Geode Capital Management, LLC (0.60%), Vanguard Fiduciary Trust Co (0.23%), UBS Group AG (0.04%).
What percentage of Aptevo Therapeutics is owned by institutions?
Institutions hold 2.9% of Aptevo Therapeutics's shares outstanding; insiders hold 4.15%.
Which funds own Aptevo Therapeutics?
The largest fund holders of Aptevo Therapeutics are Fidelity Extended Market Index (0.35%), Fidelity Series Total Market Index (0.09%).
What is Aptevo Therapeutics's short interest?
119K shares of Aptevo Therapeutics were sold short, 7.69% of the float; at the average daily volume it would take 0.62 days to cover.
Are insiders buying or selling Aptevo Therapeutics?
Of the latest 1 reported insider transactions in Aptevo Therapeutics (since November 22, 2021), 0 were purchases and 1 were sales.
How many shares of Aptevo Therapeutics are outstanding?
Aptevo Therapeutics has 1.8M shares outstanding, of which 1.7M are in the public float.